The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders. Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding during the period which includes 19,815,131 of Pre-Funded Warrants and shares held in abeyance from date of issuance.


	Three months ended March 31,
	2025			2024
Numerator:
Net loss	$	(13,678,735	)	$	(4,649,635	)
Denominator:
Weighted-average number of shares outstanding – basic and diluted		89,537,171			6,340,697
Net loss per share applicable to common stockholders – basic and diluted	$	(0.15	)	$	(0.73	)

The Company’s potentially dilutive securities have been excluded from the computation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been antidilutive for the periods presented. Therefore the weighted average number of shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The potentially dilutive securities that have been excluded from the computation of diluted net loss per share include stock options and warrants to purchase common stock, restricted common stock and shares of common stock issued as contingent consideration in connection with the acquisition of CorHepta, for which the vesting conditions have not been met. The Company excluded the following potential shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated:


	Three months ended March 31,
	2025		2024
Options to purchase shares of stock		33,899,741		846,666
Warrants to purchase shares of stock		140,790,299		2,266,136
Contingently issuable shares (see Note 10):
Restricted common stock		1,660,222		—
Contingent consideration		2,489,030		—
Total		178,839,292		3,112,802